Want to see HK:1877 full AI Analyst Report?
Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$15.00
â–Ľ(-45.53% Downside)
Action:Reiterated
Date:06/02/26
The score is driven mainly by weak financial quality: despite solid revenue growth and high gross margins, the company remains materially unprofitable with negative operating and free cash flow. Technicals add further pressure as the stock trades below major moving averages with negative MACD, indicating a prevailing downtrend. Valuation is also constrained by a negative P/E stemming from losses and no provided dividend yield.
Positive Factors
Very high gross margins
Sustained gross margins near 79% indicate strong product-level economics and pricing power typical of biologics. This margin cushion can absorb SG&A and R&D as sales scale, improving the path to durable profitability once operating leverage is achieved.
Negative Factors
Negative operating cash flow
Persistent negative operating and free cash flow indicate ongoing cash burn that requires external financing or asset monetization. This constrains investment autonomy, risks dilution from new capital, and limits ability to self-fund late-stage trials or geographic commercial expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high gross margins
Sustained gross margins near 79% indicate strong product-level economics and pricing power typical of biologics. This margin cushion can absorb SG&A and R&D as sales scale, improving the path to durable profitability once operating leverage is achieved.
Read all positive factors
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.17B
Dividend YieldN/A
Average Volume (3M)7.63M
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth34.19%
EPS Growth47.97%
CountryHK
Employees2,578
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.25Price Target Upside17.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.44
Revenue Forecast (FY)HK$3.31B
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic...
How the Company Makes Money
The company primarily makes money through (1) product sales of its commercialized medicines, where revenue is generated from selling approved drugs into end markets via its own commercialization capabilities and/or distribution channels; (2) licen...
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.71B | 2.43B | 1.95B | 1.50B | 1.45B | 4.02B |
| Gross Profit | 2.12B | 1.97B | 1.54B | 835.26M | 927.21M | 2.77B |
| EBITDA | -534.03M | -599.38M | -935.50M | -2.16B | -2.52B | -476.32M |
| Net Income | -655.78M | -851.76M | -1.28B | -2.28B | -2.39B | -718.56M |
Balance Sheet | ||||||
| Total Assets | 14.10B | 12.39B | 10.80B | 11.36B | 12.58B | 11.05B |
| Cash, Cash Equivalents and Short-Term Investments | 4.55B | 3.22B | 2.93B | 3.78B | 6.00B | 3.50B |
| Total Debt | 5.96B | 4.14B | 2.93B | 1.79B | 1.32B | 628.20M |
| Total Liabilities | 8.03B | 6.16B | 4.85B | 4.02B | 2.78B | 2.72B |
| Stockholders Equity | 5.88B | 6.03B | 5.86B | 7.17B | 9.50B | 7.96B |
Cash Flow | ||||||
| Free Cash Flow | -1.27B | -1.21B | -2.12B | -2.85B | -2.17B | -1.53B |
| Operating Cash Flow | -415.51M | -465.77M | -1.43B | -2.01B | -1.78B | -641.90M |
| Investing Cash Flow | -1.80B | -1.58B | -892.78M | -892.42M | -467.62M | -1.88B |
| Financing Cash Flow | 3.63B | 2.17B | 1.02B | 681.04M | 4.64B | 2.67B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Negative
27.54
Price Trends
21.94
Negative
21.78
Negative
24.18
Negative
Market Momentum
-1.62
Negative
29.39
Positive
30.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1877, the sentiment is Negative. The current price of 27.54 is above the 20-day moving average (MA) of 17.07, above the 50-day MA of 21.94, and above the 200-day MA of 24.18, indicating a bearish trend. The MACD of -1.62 indicates Negative momentum. The RSI at 29.39 is Positive, neither overbought nor oversold. The STOCH value of 30.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1877.
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$130.63B | 139.31 | 4.82% | ― | 38.55% | ― | |
61 Neutral | HK$30.26B | 35.94 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$60.54B | 57.71 | 42.27% | ― | 80.08% | ― | |
47 Neutral | HK$15.80B | -11.03 | -24.29% | ― | 8.50% | 35.24% | |
46 Neutral | HK$76.73B | -65.09 | -14.26% | ― | 44.03% | -108.83% | |
42 Neutral | HK$30.17B | -52.25 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.21
-3.54
-17.06%
HK:1801
Innovent Biologics
80.05
1.65
2.10%
HK:9688
Zai Lab Ltd
14.21
-13.24
-48.23%
HK:9926
Akeso, Inc.
91.65
-0.30
-0.33%
HK:9995
RemeGen Co. Ltd. Class H
79.70
25.25
46.37%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
63.05
10.25
19.41%
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Junshi Biosciences Details Valuation Basis for Assets in Joint Venture
Jun 26, 2026
Shanghai Junshi Biosciences has issued a supplemental announcement detailing the valuation methodology for assets contributed to a newly formed joint venture company under a connected transaction. The move clarifies how the company is pricing its ...
Shanghai Junshi Biosciences Shareholders Approve All Resolutions at 2025 AGM
Jun 26, 2026
Shanghai Junshi Biosciences Co., Ltd. reported the poll results of its 2025 annual general meeting in Shanghai, where all proposed resolutions were approved by shareholders. Attendance covered both A and H share classes, with nearly 30% of eligibl...
Shanghai Junshi Biosciences Restructures Board Roles and Governance Committees
Jun 26, 2026
Shanghai Junshi Biosciences has updated the composition of its board of directors, detailing a leadership structure that includes a chairman, vice chairman, co-chief executive officer and several executive, non-executive and independent non-execut...
Shanghai Junshi Biosciences reshapes board and committees to bolster governance
Jun 26, 2026
Shanghai Junshi Biosciences has strengthened its board structure with the election of Chen Liang as an independent non-executive director, effective June 26, 2026, following shareholder approval at the annual general meeting. His appointment, gove...
Junshi Biosciences Discloses Equity Reduction by Major Shareholder Group
Jun 15, 2026
Shanghai Junshi Biosciences Co., Ltd. announced changes in the shareholding of major investor Shanghai Tanying Investment Partnership (LP) and its concerted parties, which collectively reduced their equity stake in the company. Following the trans...
Shanghai Junshi Biosciences Sets Up Connected JV to House Key IP Assets
Jun 5, 2026
Shanghai Junshi Biosciences plans to form a joint venture with Suzhou Union, Junshi Biotechnology, Suzhou Junmeng, a JV company and non-executive director Dr. Yao, contributing licensed intellectual property, tangible assets and related IP rights....
Shanghai Junshi Biosciences Calls 2025 AGM and Seeks Mandate for RMB 2.5 Billion Debt Issuance
Jun 5, 2026
Shanghai Junshi Biosciences has called its 2025 annual general meeting for 26 June 2026 in Shanghai to seek shareholder approval on a wide range of corporate matters, including the 2025 annual report, profit distribution plan, dividend policy for ...
Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM
Jun 5, 2026
Shanghai Junshi Biosciences has announced the closure of its H share register from 23 June 2026 to 26 June 2026, during which no transfers of H shares will be processed. This measure is to determine which H share investors are entitled to attend a...
Shanghai Junshi Biosciences Reassigns Dr. Yao Sheng to Non-Executive Director Role
Jun 5, 2026
Shanghai Junshi Biosciences announced that Dr. Yao Sheng has resigned as deputy general manager and as a director of its subsidiary Suzhou Junao Precision Medicine due to other work arrangements, and has been re-designated from an executive direct...
Junshi Biosciences Sets Out Board Composition and Committee Roles
Jun 5, 2026
Shanghai Junshi Biosciences has detailed the composition of its board of directors, listing a mix of executive, non-executive and independent non-executive members, including a chairman, vice chairman and co-chief executive officers. The disclosur...
Junshi Biosciences Reshapes Ownership of Key R&D Subsidiary Without Changing Fund Use
Jun 5, 2026
Shanghai Junshi Biosciences has announced changes to the shareholding structure of its subsidiary Ningbo Junyan Hongshi Biomedical Technology, which serves as an implementing entity for certain innovative drug RD sub-projects financed by its 2022 ...
Junshi’s Toripalimab Hits Phase III Goal in Perioperative Lung Cancer Study
May 26, 2026
Shanghai Junshi Biosciences has reported that its PD-1 inhibitor toripalimab, marketed as TUOYI, achieved the primary endpoints in the final analysis of the phase III NEOTORCH study as perioperative therapy for resectable stage II-III non-small ce...
Junshi Wins NMPA Nod for Toripalimab Combo in First-Line HER2-Positive Urothelial Cancer
May 21, 2026
Shanghai Junshi Biosciences has received approval from China’s National Medical Products Administration for a supplemental new drug application expanding toripalimab’s use, in combination with RemeGen’s antibody-drug conjugate di...
Junshi Biosciences Launches 2026 A Share Employee Stock Ownership Scheme
Apr 27, 2026
Shanghai Junshi Biosciences has approved the adoption of a 2026 A Share Employee Stock Ownership Scheme aimed at aligning employee and shareholder interests, improving corporate governance, and enhancing staff cohesion and competitiveness. The sch...
Junshi Biosciences posts strong Q1 revenue growth and sharply reduced loss
Apr 27, 2026
Shanghai Junshi Biosciences has released an overseas regulatory announcement providing an English translation of its unaudited 2026 first-quarter financial report, prepared under PRC accounting standards for the STAR Market. The company reported o...
Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting
Apr 27, 2026
Shanghai Junshi Biosciences Co., Ltd. has disclosed an overseas regulatory announcement in Hong Kong, aligning its Hong Kong disclosure with information released on the Shanghai Stock Exchange. The notice reiterates the company’s compliance ...
Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction
Apr 23, 2026
Shanghai Junshi Biosciences announced that shareholder Shanghai Tanying Investment Partnership (LP), a private equity fund and pre-IPO investor, currently holds 59,459,326 A shares, representing 5.7914% of the company’s total share capital, ...
Junshi Biosciences Adds Subsidiary to Lead Key Innovative Drug R&D Projects
Apr 21, 2026
Shanghai Junshi Biosciences Co., Ltd. has designated its wholly owned subsidiary Ningbo Junyan Hongshi Biomedical Technology Co., Ltd. as an additional implementing entity for certain sub-projects within its innovative drug RD investment program, ...
Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results
Apr 15, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to review and approve the group’s unaudited financial results for the three months ended March 31, 2026. The announcement signals the upcoming release of...
Junshi Biosciences’ Major Shareholder Lets Share-Sale Plan Expire Unused
Apr 10, 2026
Shanghai Junshi Biosciences has announced that a planned shareholding reduction by substantial shareholder Shanghai Tanying Investment Partnership (LP), which held 5.79% of the company’s total share capital in A shares, has reached its expir...
Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase
Mar 31, 2026
Shanghai Junshi Biosciences has disclosed that its chairman, controlling shareholder and actual controller, Xiong Jun, has completed a planned increase in his holdings of both A shares and H shares of the company. The plan, launched on 12 April 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.